Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 11/20 | 0.60 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3631830 | 0.89 | CCR1 (0.60) | CCR1MAPTSMN1; SMN2 | |
| SCHEMBL13417644 | 0.85 | CCR1 (0.57) | CCR1MAPTSMN1; SMN2 | |
| SCHEMBL12765632 | 0.85 | CCR1 (0.65) | CCR1ALK | |
| SCHEMBL1639577 | 0.85 | CCR1 (0.69) | CCR1 | |
| SCHEMBL1911902 | 0.84 | TGFBR1 (0.54) | ALKMAPT | |
| SCHEMBL4281721 | 0.84 | QDPR (0.59) | ALKMAPT | |
| SCHEMBL18711281 | 0.83 | MAPT (0.70) | ALKMAPTSMN1; SMN2 | |
| SCHEMBL2205957 | 0.83 | CASP6 (0.59) | ALKMAPT | |
| SCHEMBL1639007 | 0.83 | SUV39H2 (0.60) | CCR1ALKMAPTSMN1; SMN2SUV39H2 | |
| SCHEMBL14724221 | 0.82 | CCR1 (0.62) | CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324216-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-7842693-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-7671069-B2 | Tricyclic, heteroaromatic compounds modulating CXCR4 and/ or CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| EP-1531822-B1 | 1-ARYL-4-SUBSTITUTED PIPERAZINE DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | CHEMOCENTRYX INC (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-1691810-A4 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX INC (US) | 2009-07-01 | — | — | EP | disclosed |
| US-7449576-B1 | potent antagonists of the CCR1 receptor; inflammation; (5-Chloro-2-piperazin-1-yl-phenyl)-phenyl-methanone | CHEMOCENTRYX, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080261987-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-7157464-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1691810-A1 | SUBSTITUTED PIPERAZINES | ChemoCentryx Inc (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060106218-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-20050256130-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| WO-2005056015-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20040162282-A1 | Substituted piperazines | CHEMOCENTRYX, INC. | 2004-08-19 | — | — | US | disclosed |
| US-20040082571-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261987-A1 | SUBSTITUTED PIPERAZINES | CCR1, CCR3, CCRL2 | CCR1 1/4885ALK 1554/4885MAPT 3524/4885 |
| US-20040082571-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | CCR1 1/4885ALK 1554/4885MAPT 3524/4885 |
| US-20060106218-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | CCR1 1/4885ALK 2664/4885MAPT 4063/4885 |
| US-20050256130-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | CCR1 1/4885ALK 2664/4885MAPT 4063/4885 |
| US-20040162282-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | CCR1 1/4885ALK 1554/4885MAPT 3524/4885 |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CCR1, CCR3, CCRL2 | CCR1 1/4885ALK 2664/4885MAPT 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.